Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA6 | P23280 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | TPMT | P51580 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213459 | 0.93 | HTT (0.64) | HTTTSHRMAPTCA12CA1 | |
| SCHEMBL27620944 | 0.89 | MAPT (0.67) | HTTTSHRMAPTCA12CA1 | |
| SCHEMBL2791210 | 0.89 | MAPT (0.82) | HTTTSHRMAPTCA12CA1 | |
| SCHEMBL21114354 | 0.88 | CA12 (0.69) | HTTTSHRMAPTCA12CA1 | |
| Vanillic Acid SCHEMBL9711598 | 0.87 | HTT (1.00) | HTTTSHRMAPTCA12CA1 | |
| Vanillic Acid SCHEMBL26179 | 0.87 | HTT (1.00) | HTTTSHRMAPTCA12CA1 | |
| Vanillic Acid SCHEMBL29378740 | 0.87 | HTT (1.00) | HTTTSHRMAPTCA12CA1 | |
| Vanillic Acid SCHEMBL6697041 | 0.85 | HTT (0.96) | HTTTSHRCA12CA1CA2 | |
| Vanillic Acid SCHEMBL17443329 | 0.85 | HTT (0.96) | HTTTSHRCA12CA1CA2 | |
| Vanillic Acid SCHEMBL18334646 | 0.85 | HTT (0.96) | HTTTSHRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067571-A1 | CO - CRYSTALS OF A TRIAZOLO [4,5 - D] PYRIMIDINE PLATELET AGGREGATION INHIBITOR | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | WO | claimed |
| US-20120014883-A1 | Compositions Comprising Derivatives Of Essential Oil Compounds And Use In Personal Care Products | THE PROCTER & GAMBLE COMPANY | 2012-01-19 | — | — | US | disclosed |
| US-20110288161-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2011-11-24 | — | — | US | disclosed |
| EP-2383330-A1 | A stabilized liquid enzyme composition | Novozymes A/S (DK) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011067571-A1 | CO - CRYSTALS OF A TRIAZOLO [4,5 - D] PYRIMIDINE PLATELET AGGREGATION INHIBITOR | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067571-A1 | CO - CRYSTALS OF A TRIAZOLO [4,5 - D] PYRIMIDINE PLATELET AGGREGATION INHIBITOR | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011064237-A1 | CRYSTALLINE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-20110104305-A1 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | DAY BRIAN J | 2011-05-05 | — | — | US | disclosed |
| WO-1992017550-A1 | BIODEGRADABLE AZO DYES | IDAHO RESEARCH FOUNDATION, INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288161-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | ABCC1, SLC47A2, SLC47A1 | HTT 987/4885TSHR 4043/4885MAPT 3843/4885 |
| US-20110104305-A1 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | ABCC1, ABCC2, ABCB1 | HTT 2358/4885TSHR 3356/4885MAPT 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.